EUVIMEDEUVIMED entdecken
Crossref

Retinal Vein Occlusion (RVO): Outcomes of Anti-VEGF vs Steroid Treatment for Macular Edema

Alka Ravi, Anurag Das, Prakash Kumar Keshav, Ramakant Thakur

International Journal of Current Pharmaceutical Review and Research · 31.03.2026 · 18 (03)

DOI: 10.25258/ijcpr.18.3.288 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 31.03.2026. Verfasst von Alka Ravi und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Retinal vein occlusion (RVO) is the second most common retinal vascular disorder after diabetic retinopathy and a major cause of visual impairment worldwide. Macular edema is the principal cause of vision loss in RVO. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents and intravitreal corticosteroids are the most widely used treatment modalities for RVO-related macular edema. However, comparative clinical outcomes between these therapies remain a subject of ongoing clinical interest.

Aim

To compare the visual and anatomical outcomes of anti-VEGF therapy and intravitreal steroid treatment in patients with macular edema secondary to retinal vein occlusion.

Methods

A hospital-based prospective observational study was conducted at Government Medical College & Hospital, West Champaran, Bettiah, Bihar, India from 5th March 2025 to 25th February 2026. A total of 150 patients with RVO-associated macular edema were enrolled. Patients were divided into two treatment groups: anti-VEGF group (n=80) and steroid group (n=70). Outcomes assessed included best corrected visual acuity (BCVA), central macular thickness (CMT) measured by optical coherence tomography (OCT), and treatmentrelated adverse events over a 6-month follow-up period.

Results

Both treatment groups showed significant improvement in BCVA and reduction in CMT. The anti-VEGF group demonstrated a greater improvement in visual acuity (mean BCVA improvement 0.32 ± 0.09 logMAR) compared with the steroid group (0.25 ± 0.08 logMAR, p

Zitieren

APA

Ravi, A., Das, A., Keshav, P. K., & Thakur, R. (2026). Retinal Vein Occlusion (RVO): Outcomes of Anti-VEGF vs Steroid Treatment for Macular Edema. International Journal of Current Pharmaceutical Review and Research, 18(03). https://doi.org/10.25258/ijcpr.18.3.288

Vancouver

Ravi A, Das A, Keshav PK, Thakur R. Retinal Vein Occlusion (RVO): Outcomes of Anti-VEGF vs Steroid Treatment for Macular Edema. International Journal of Current Pharmaceutical Review and Research. 2026;18(03). doi:10.25258/ijcpr.18.3.288

BibTeX
@article{Ravi2026,
  author = {Ravi, Alka and Das, Anurag and Keshav, Prakash Kumar and Thakur, Ramakant},
  title = {Retinal Vein Occlusion (RVO): Outcomes of Anti-VEGF vs Steroid Treatment for Macular Edema},
  journal = {International Journal of Current Pharmaceutical Review and Research},
  year = {2026},
  volume = {18},
  number = {03},
  doi = {10.25258/ijcpr.18.3.288}
}
Kostenlos starten →